BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15950811)

  • 1. Implications of P16/CDKN2A deletion in pleural mesotheliomas.
    Ladanyi M
    Lung Cancer; 2005 Jul; 49 Suppl 1():S95-8. PubMed ID: 15950811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
    Illei PB; Rusch VW; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.
    López-Ríos F; Chuai S; Flores R; Shimizu S; Ohno T; Wakahara K; Illei PB; Hussain S; Krug L; Zakowski MF; Rusch V; Olshen AB; Ladanyi M
    Cancer Res; 2006 Mar; 66(6):2970-9. PubMed ID: 16540645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
    Illei PB; Ladanyi M; Rusch VW; Zakowski MF
    Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
    Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
    Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
    Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
    Flores-Staino C; Darai-Ramqvist E; Dobra K; Hjerpe A
    Lung Cancer; 2010 Apr; 68(1):39-43. PubMed ID: 19523712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
    Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Nonomura A
    Pathol Int; 2010 May; 60(5):395-9. PubMed ID: 20518890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
    Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
    Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
    Chiosea S; Krasinskas A; Cagle PT; Mitchell KA; Zander DS; Dacic S
    Mod Pathol; 2008 Jun; 21(6):742-7. PubMed ID: 18327208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
    Krasinskas AM; Bartlett DL; Cieply K; Dacic S
    Mod Pathol; 2010 Apr; 23(4):531-8. PubMed ID: 20081810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
    Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.
    Chen ZH; Zhang H; Savarese TM
    Cancer Res; 1996 Mar; 56(5):1083-90. PubMed ID: 8640765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.
    Hwang H; Tse C; Rodriguez S; Gown A; Churg A
    Am J Surg Pathol; 2014 May; 38(5):681-8. PubMed ID: 24503757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
    Dacic S; Kothmaier H; Land S; Shuai Y; Halbwedl I; Morbini P; Murer B; Comin C; Galateau-Salle F; Demirag F; Zeren H; Attanoos R; Gibbs A; Cagle P; Popper H
    Virchows Arch; 2008 Dec; 453(6):627-35. PubMed ID: 18958493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
    Chung CT; Santos Gda C; Hwang DM; Ludkovski O; Pintilie M; Squire JA; Tsao MS
    J Clin Pathol; 2010 Jul; 63(7):630-4. PubMed ID: 20591913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
    Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
    Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
    Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
    Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.